Cannabidiol (CBD) for the Management of Cannabis Withdrawal: A Phase II Proof of Concept Study
Status:
Unknown status
Trial end date:
2014-12-01
Target enrollment:
Participant gender:
Summary
Single subject repeated measures design of an open label administration of Cannabidiol (CBD)
to 5 participants withdrawing from cannabis use in an inpatient setting. 300mg of CBD will be
administered once on day 1, twice on days 2-5 and once on day 6. Participants will be
discharged on day 7. CBD will be administered orally in capsules.